Molecular Testing Software Reduces Time to qPCR-Based Diagnostic Results by Over Two Hours
Posted on 14 Jul 2023
Clinical laboratories and kit producers specializing in molecular diagnostics often struggle with outdated systems that are challenging to scale up for increased workload or diversified testing offerings. Additionally, cumbersome and inefficient procedures may hinder sample tracking and compliance maintenance, which are crucial for molecular diagnostic labs. For assay developers, shifts between developmental stages and the absence of process standardization can slow down market readiness and risk regulatory compliance. Now, a new scalable software designed to address challenges with error-prone, manual molecular testing workflows helps streamline routine diagnostics testing for standardization and faster time-to-results.
Thermo Fisher Scientific (Waltham, MA, USA) has introduced Diomni Enterprise Software which enhances a lab's adaptability to the rapidly evolving testing requirements by integrating workflow steps within a single interface. This solution is suitable for a wide range of labs that perform regular quantitative polymerase chain reaction (qPCR) diagnostic tests, as well as developers aiming to expedite the development of novel testing solutions. Diomni Enterprise seamlessly connects the individual steps of the workflow into a single integrated platform, thus improving the productivity of qPCR workflows.
Diomni Enterprise enables labs to function at maximum efficiency by automating the interface with existing laboratory information systems (LIS), thus boosting efficiency and traceability. By consolidating labs, instruments, assays, and LIS within one system, the software enhances traceability, facilitating sample and reagent tracking throughout the sample's journey. It also allows multiple users to simultaneously access assay templates and results. Diomni Enterprise supports a diverse range of testing workflows and is compatible with both research-use-only and in vitro diagnostic assays and instruments.
“During the pandemic, we worked to quickly launch a digital solution that would allow clinical labs to continue operations, taking into account the dramatic changes in the PCR testing landscape,” said Fernando Beils, vice president, general manager of qPCR instruments, Thermo Fisher Scientific. “What followed was the earliest stages of the Diomni solution, delivering a digital platform that supports testing workflows with the flexibility required to accommodate rapidly evolving needs. We have continued to build on this platform and are excited to deliver a more robust and scalable tool for labs and assay developers across testing environments.”
Related Links:
Thermo Fisher Scientific
